Global Ophthalmic Drugs Market to Expand at 5.2% CAGR


Posted December 9, 2015 by Vikash123

The global ophthalmic drugs market to reach US$21.6 billion by 2018, expanding at a CAGR of 5.2% between 2013 and 2018. The ophthalmic drugs market is primarily driven by growing prevalence of eye disorders, especially among the geriatric population.

 
According to a recent market study published by Transparency Market Research (TMR), the global ophthalmic drugs market to reach US$21.6 billion by 2018, expanding at a CAGR of 5.2% between 2013 and 2018.The report, titled “Ophthalmic Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2018”, reveals that the worldwide ophthalmic drugs market stood at US$16 billion in 2012.

High incidence of lifestyle diseases, technological advancements in techniques of drug delivery, high prevalence of eye disorders, and a growing global geriatric population are the main factors that propel the global ophthalmic drugs market. Greater government initiatives towards the development of healthcare infrastructure are the prominent factor driving the ophthalmic drugs market in most developing economies. Ongoing market trends suggest that the global ophthalmic drugs market will expand at a 5.2% CAGR from 2013 to 2018, thereby reaching US$21.6 bn by 2018, from a market value of US$16 bn in 2012.

Browse Full Press Release: http://www.transparencymarketresearch.com/pressrelease/ophthalmic-drugs-market.htm

Growing Demand for Anti-Glaucoma Drugs to Drive Market
The global ophthalmic drugs market is segmented on the basis of type of treatment drugs and geography. Over-the-counter and prescription are the two main types of drugs that dominate the global ophthalmic drugs market. On the basis of type of treatment drugs, the global ophthalmic drugs market is categorized into dry eye drugs, retinal drugs, anti-glaucoma drugs, and ophthalmic anti-allergy/inflammatory/infective drugs.

The segment of anti-glaucoma drugs holds the highest share in the global ophthalmic drugs market and is projected to expand during the forecast period as well. The market for anti-glaucoma drugs is anticipated to expand at a 4.2% CAGR during the forecast period. At present, the global ophthalmic drugs market is characterized by greater focus on combination therapy and greater number of mergers and acquisitions. The growing trend of business ventures in the ophthalmic drugs market contributes significantly to the overall market performance.

Get Free Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1769

North America: Largest Regional Player in the Global Ophthalmic Drugs Market

Geographically, the global ophthalmic drugs market is segmented into North America, Europe, Asia Pacific, and Rest of the World. The global ophthalmic drugs market is led by North America. Europe holds the second highest share in the global ophthalmic drugs market after North America. Technological advancements, the presence of a large pool of industry players, and increasing government support are the prominent factors that fuel the North America market for ophthalmic drugs.

Browse the full Ophthalmic Drugs Market (Dry eye, Anti-glaucoma, Anti-allergy/inflammatory/infective, Retinal Drugs) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2018 report athttp://www.transparencymarketresearch.com/ophthalmic-drugs-market.html

Owing to the rising prevalence of blindness amongst the rapidly expanding geriatric population, the Asia Pacific market for ophthalmic drugs is expected to register the highest rate of growth during the forecast period. Major countries in Southeast Asia, such as China and India, are a few of the largest consumers of ophthalmic drugs in the world and the growing demand for ophthalmic drugs from these countries is expected to fuel the global ophthalmic drugs market in the forthcoming years. The prominent companies operating in the global ophthalmic drugs market are Allergan, Roche, Merck, Novartis, Pfizer, and Santen Pharmaceutical. In 2012, Novartis alone held a market share of approximately 24% in the overall ophthalmic drugs market.

About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Sudip Saha
Country United States
Categories Health
Last Updated December 9, 2015